Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NeoCellBank

Financiado

Cerrado

A revolutionary regenerative therapy for management of chronic inflammatory dise...

A revolutionary regenerative therapy for management of chronic inflammatory diseases based on neonatal Mesenchymal Stem Cells Society is experiencing a rise in chronic inflammatory diseases, mostly due to ageing, and sedentary lifestyle. Osteoarthritis (OA) is one of the leading inflammatory diseases, affecting both humans (incidence 15%) and pets (20%),... ver más

31/08/2019

VETBIOBANK SAS

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

VETBIOBANK SAS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 6 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-08-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

VETBIOBANK SAS

50.00K€ | Lider

ALIATIS, S.L.

381.30K€ | Participante

EMERGYA INGENIERÍA

444.85K€ | Participante

PULSIA TECHNOLOGY

1.02M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

STEMREPAIR Novel mesenchymal stem cell based therapies for articular ca... 1M€ Cerrado

ADIPOA2 Clinical trial of autologous adipose derived mesenchymal str... 6M€ Cerrado

PID2020-113910RB-I00 CONDICIONAMIENTO BIOFISICO DE CELULAS MADRE/ESTROMALES MESEN... 218K€ Cerrado

REGENER-AR Bringing Regenerative Medicine into the market Allogeneic e... 8M€ Cerrado

PTQ-10-02589 ASCFORMSTHERAPY-CÉLULAS MADRE MESENQUIMALES DERIVADAS DE TEJ... 55K€ Cerrado

SAF2013-48724-R MECANISMOS CELULARES REGULADORES DE LA RESPUESTA INFLAMATORI... 163K€ Cerrado

Duración del proyecto: 4 meses Fecha Inicio: 2019-04-29
Fecha Fin: 2019-08-31

Líder del proyecto

VETBIOBANK SAS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Society is experiencing a rise in chronic inflammatory diseases, mostly due to ageing, and sedentary lifestyle. Osteoarthritis (OA) is one of the leading inflammatory diseases, affecting both humans (incidence 15%) and pets (20%), incurring disability and large economic burden. Current pharmacological treatments for OA involve palliative therapies (NSAIDs) that work on the symptoms, becoming lengthy and expensive with multiple side effects. In this context, regenerative medicine based on stem cells appears as a good alternative, as they reverse the pro-inflammatory status of the joint and promote endogenous tissue regeneration. However, current solutions for OA mainly rely on autologous adult stem cells, obtained through invasive procedures and which hold biological properties altered by donor age and underlying inflammation. Allogeneic adult cells could be used in any individual, but a limited amplification potential limits the number of recipients. In response, we aim to revolutionize the field of regenerative medicine by introducing a unique cell therapy based on neonatal stem cells. These cells have many advantages over adult cells: source material is accessible & abundant, cells show stronger anti-inflammatory properties, and lower immunogenicity profile which allows for unrestricted allogeneic use. The main goal of our project is to finalise industrialization and bring to market our reliable cell-based solution for OA. In Phase 1 we will define the technical and commercial steps to overcome before reaching mature stage. Upon completion of this project, we foresee our product to disrupt the veterinary market of inflammatory diseases. Moreover, since the pathology mechanism for OA is shared between animals and humans, our product could work as an accelerator for human applications. Importantly, the effort will pay off for Vetbiobank, estimating to earn €26 million profits, hire 19 people and reach a Return of Investment of 4.2 Euros after 5 years in the market.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores